CompletedNot Applicable

Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors

United States16 participantsStarted 2004-08

Plain-language summary

RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying changes in semen or sperm caused by temozolomide in patients with newly diagnosed, progressive, or recurrent primary malignant brain tumors.

Who can participate

Age range18 Years – 60 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed primary malignant brain tumor * Newly diagnosed, progressive, or recurrent disease * May have received prior radiotherapy with or without chemotherapy * Scheduled to begin single-agent temozolomide chemotherapy * Must be able to ejaculate * Must abstain from ejaculating (e.g., not have sex or masturbate) for 2-7 days prior to study * No known abnormal sperm motility and/or morphology PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% PRIOR CONCURRENT THERAPY: * See Disease Characteristics

What they're measuring

assess any changes in standard semen/sperm analysis parameters

Timeframe: 6 months

Trial details

NCT IDNCT00499798

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-06

View on ClinicalTrials.gov More Brain and Central Nervous System Tumors trials